The frequency of RAS and NF1 mutations varies depending on the tumor tissue of origin: in melanoma, due to the lower endogenous baseline RAS activity, class III BRAF mutations almost always coexist with mutated RAS or NF1. This evidence concerns the gene BRAF and neoplasm.